EPISODE · Jan 3, 2019 · 12 MIN

CAR T-cell therapy

from Listen to The Lancet Oncology · host The Lancet

Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Episode metadata supplied by the publisher feed · Published Jan 3, 2019

Embed this episode

Attribution link and audio player

NOW PLAYING

CAR T-cell therapy

0:00 12:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 12 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on January 3, 2019.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!